Oncologie, Mologen negotiating larger lefitolimod deal

Mologen AG (Xetra:MGNK) and Oncologie Inc. (Cayman Islands) agreed on Aug. 17 to a three month period to negotiate a deal granting Oncologie exclusive, worldwide rights to Mologen's lead compound lefitolimod (MGN1703). In February, Oncologie received exclusive, global co-development rights and rights to develop, manufacture and commercialize lefitolimod in China, Hong Kong, Macao, Taiwan and Singapore (see "Oncologie Gains Rights to Mologen's Lefitolimod").

Mologen said a deal would secure the "major part of funding" for the Phase III IMPALA trial evaluating the compound to treat metastatic colorectal cancer (mCRC). Data are due in 2020...